Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07276373 · ClinicalTrials.gov registry record · Phase 1
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
A Phase 1 study of Neoplasms, sponsored by Corcept Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT07276373 is a Phase 1 study of Neoplasms that is actively recruiting participants, run by Corcept Therapeutics. The registered enrollment target is 50 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07276373, a Phase 1 study of Neoplasms, is actively recruiting participants, sponsored by Corcept Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Nenocorilant 200 mg
- DRUG Nenocorilant 300 mg
- DRUG Nenocorilant 400 mg
Study Locations (3)
California
- Site 03 - Los Angeles
Texas
- Site 01 - San Antonio
Utah
- Site 02 - West Valley City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-01-16 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07276373
The ClinicalTrials.gov registry entry for NCT07276373 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Nivolumab is the first listed.
NCT07276373 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT07276373 about?
NCT07276373 is a clinical study titled "Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies". This open-label, dose-finding, and proof of concept study will evaluate the safety, tolerability, maximum-tolerated dose (MTD) and/or optimal dose of nenocorilant when administered in combination with nivolumab in patients with advanced solid malignancies.
What is the current status of trial NCT07276373?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-01-16. Estimated completion is 2027-01.
What conditions does trial NCT07276373 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT07276373?
The interventions under investigation include: Nivolumab (DRUG), Nenocorilant 200 mg (DRUG), Nenocorilant 300 mg (DRUG), Nenocorilant 400 mg (DRUG).
Who is sponsoring clinical trial NCT07276373?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07276373 being conducted?
This trial has 3 study locations across California, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
-
Phase 1 Study of JV-394 Autologous Anti-CD94 CAR T for r/r CD94+ T/NK Cell Neoplasms
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.